Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

A Randomized, Placebo Controlled, Double-blind, Double-dummy, Three-way Crossover Trial to Investigate the Effect of Two Doses of BI 474121 on Ketamine Induced Cognitive Deficits in Healthy Male Subjects

To see complete record on, please visit this link

Id: NCT05451095

Organisation Name: Boehringer Ingelheim

Overal Status: Withdrawn

Start Date: November 7, 2022

Last Update: August 1, 2022

Lead Sponsor: Boehringer Ingelheim

Brief Summary: To investigate the effect of BI 474121 compared to placebo on ketamine-induced cognitive deficits to predict efficacy in patients with cognitive disorders.

  • Healthy

Total execution time in seconds: 0.27421116828918